Seek Returns

NBIX vs. PCVX: Neurocrine Biosciences vs. Vaxcyte Stock Comparison

How do Neurocrine Biosciences (NBIX) and Vaxcyte (PCVX) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

Neurocrine Biosciences (NBIX) and Vaxcyte (PCVX) are both classified in the Biotechnology sub-industry within the broader Biotechnology industry, placing them in the closest GICS peer bucket.

Neurocrine Biosciences (NBIX) has more than two decades of public-market history since May 23, 1996, whereas Vaxcyte (PCVX) listed on June 12, 2020 and has a much shorter record to draw on.

Company profile comparison for Neurocrine Biosciences (NBIX) and Vaxcyte (PCVX)
Profile ItemNBIXPCVX
NameNeurocrine Biosciences, Inc.Vaxcyte Inc.
Country/RegionUnited StatesUnited States
GICS SectorHealth CareHealth Care
GICS Industry GroupPharmaceuticals, Biotechnology & Life SciencesPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnologyBiotechnology
GICS Sub-IndustryBiotechnologyBiotechnology
Market Capitalization16.66 billion USD10.11 billion USD
CurrencyUSDUSD
ExchangeNasdaqNasdaq
Listing DateMay 23, 1996June 12, 2020
Security TypeCommon StockCommon Stock

Price Performance

Cumulative Growth

NBIX
PCVX
GSPC
Loading price history…
Neurocrine Biosciences (NBIX) vs. Vaxcyte (PCVX), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…
Trailing total returns for Neurocrine Biosciences (NBIX) and Vaxcyte (PCVX). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…
Calendar-year total returns for Neurocrine Biosciences (NBIX) and Vaxcyte (PCVX). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for Neurocrine Biosciences (NBIX) and Vaxcyte (PCVX)
MetricNBIXPCVX
Total Return (1Y)9.40%59.00%
Total Return (3Y, Annualized)14.12%11.29%
Total Return (5Y, Annualized)12.61%21.60%

Risk Profile

Drawdown History

NBIX
PCVX
GSPC
Loading price history…
Neurocrine Biosciences (NBIX) vs. Vaxcyte (PCVX), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…
Distribution of monthly total returns for Neurocrine Biosciences (NBIX) and Vaxcyte (PCVX). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Risk profile metrics for Neurocrine Biosciences (NBIX) and Vaxcyte (PCVX)
MetricNBIXPCVX
Volatility (1Y, Annualized)35.05%56.01%
Beta (5Y)0.291.26
Max Drawdown (5Y)-42.89%-76.22%
Avg. Volume (3M)1.31M2.12M

Risk-Adjusted Performance

Risk-Return Positioning

Loading chart…
NBIX and PCVX are plotted by 1-year volatility (risk) and 1-year return. The dashed Capital Allocation Line runs from the risk-free rate through the shared industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for Neurocrine Biosciences (NBIX) and Vaxcyte (PCVX)
MetricNBIXPCVX
Sharpe Ratio (1Y)0.150.98
Sortino Ratio (1Y)0.221.76

Profitability

ROE (TTM)

Vaxcyte (PCVX) reports a negative ROE of -42.68%; negative ROE can reflect losses or negative shareholders’ equity, so it is harder to read as capital efficiency. Meanwhile Neurocrine Biosciences (NBIX) reports 20.42%, ranking against industry peers normally.

NBIX

Pharmaceuticals, Biotechnology & Life Sciences industry group

20.42%

Max
109.18%
NBIX
20.42%
Q3
6.23%
Median
-26.66%
Q1
-64.05%
Min
-167.77%

PCVX

Pharmaceuticals, Biotechnology & Life Sciences industry group

-42.68%

Max
109.18%
Q3
6.23%
Median
-26.66%
PCVX
-42.68%
Q1
-64.05%
Min
-167.77%
Loading chart…
Neurocrine Biosciences (NBIX) vs. Vaxcyte (PCVX): A comparison of their ROE against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Net Margin (TTM)

Neurocrine Biosciences (NBIX) at 18.98% converts revenue to bottom-line profit above its industry’s benchmark range, while Vaxcyte (PCVX) at 0.00% keeps roughly the typical share for its industry.

NBIX

Pharmaceuticals, Biotechnology & Life Sciences industry group

18.98%

NBIX
18.98%
Max
18.05%
Q3
4.78%
Median
0.00%
Q1
-4.14%
Min
-17.05%

PCVX

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

Max
18.05%
Q3
4.78%
PCVX
0.00%
Median
0.00%
Q1
-4.14%
Min
-17.05%
Loading chart…
Neurocrine Biosciences (NBIX) vs. Vaxcyte (PCVX): A comparison of their net margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Operating Margin (TTM)

Neurocrine Biosciences (NBIX) at 31.98% operates in the top operating margin quartile, ahead of Vaxcyte (PCVX) at 0.00%, which runs around its industry’s norm.

NBIX

Pharmaceuticals, Biotechnology & Life Sciences industry group

31.98%

Max
83.12%
NBIX
31.98%
Q3
14.77%
Median
0.00%
Q1
-78.82%
Min
-207.40%

PCVX

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

Max
83.12%
Q3
14.77%
PCVX
0.00%
Median
0.00%
Q1
-78.82%
Min
-207.40%
Loading chart…
Neurocrine Biosciences (NBIX) vs. Vaxcyte (PCVX): A comparison of their operating margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Profitability Metrics

Profitability metrics for Neurocrine Biosciences (NBIX) and Vaxcyte (PCVX)
MetricNBIXPCVX
ROE (TTM)20.42%-42.68%
ROA (TTM)12.45%-24.98%
Net Margin (TTM)18.98%0.00%
Operating Margin (TTM)31.98%0.00%
Gross Margin (TTM)64.67%0.00%

Growth

Revenue Growth

Only one side can be read here: Neurocrine Biosciences (NBIX) reports revenue growth of 21.45%, ranked against its industry; Vaxcyte (PCVX) has no revenue growth figure this period.

Loading chart…
Neurocrine Biosciences (NBIX) vs. Vaxcyte (PCVX): A comparison of their Revenue Growth across different time periods.

EPS Growth

Only one side can be read here: Neurocrine Biosciences (NBIX) reports EPS growth of 41.95%, ranked against its industry; Vaxcyte (PCVX) has no EPS growth figure this period.

Loading chart…
Neurocrine Biosciences (NBIX) vs. Vaxcyte (PCVX): A comparison of their EPS Growth across different time periods.

Growth Metrics

Growth metrics for Neurocrine Biosciences (NBIX) and Vaxcyte (PCVX)
MetricNBIXPCVX
Revenue Growth (YoY)21.45%--
Revenue Growth (3Y CAGR)24.32%--
EPS Growth (YoY)41.95%--
EPS Growth (3Y CAGR)44.12%--

Financial Strength

Current Ratio (MRQ)

Vaxcyte (PCVX) at 4.56 keeps current ratio within its industry’s typical mid-range, while Neurocrine Biosciences (NBIX) at 2.04 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for NBIX.

NBIX

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.04

Max
25.13
Q3
12.13
Median
5.52
Q1
2.47
NBIX
2.04
Min
0.10

PCVX

Pharmaceuticals, Biotechnology & Life Sciences industry group

4.56

Max
25.13
Q3
12.13
Median
5.52
PCVX
4.56
Q1
2.47
Min
0.10
Loading chart…
Neurocrine Biosciences (NBIX) vs. Vaxcyte (PCVX): A comparison of their current ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Debt / Equity (MRQ)

Both Neurocrine Biosciences (NBIX) at 0.12 and Vaxcyte (PCVX) at 0.09 fund their balance sheets with roughly industry-typical debt-to-equity mixes.

NBIX

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.12

Max
1.42
Q3
0.65
Median
0.15
NBIX
0.12
Q1
0.02
Min
0.00

PCVX

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.09

Max
1.42
Q3
0.65
Median
0.15
PCVX
0.09
Q1
0.02
Min
0.00
Loading chart…
Neurocrine Biosciences (NBIX) vs. Vaxcyte (PCVX): A comparison of their debt-to-equity ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Financial Strength Metrics

Financial strength metrics for Neurocrine Biosciences (NBIX) and Vaxcyte (PCVX)
MetricNBIXPCVX
Current Ratio (MRQ)2.044.56
Debt / Equity (MRQ)0.120.09
Net Debt / EBITDA-0.27--

Dividends

Dividend Yield (TTM)

Neither Neurocrine Biosciences (NBIX) nor Vaxcyte (PCVX) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

NBIX

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

NBIX
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

PCVX

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

PCVX
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
Neurocrine Biosciences (NBIX) vs. Vaxcyte (PCVX): A comparison of their dividend yield against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Payout Ratio (TTM)

Neither Neurocrine Biosciences (NBIX) nor Vaxcyte (PCVX) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

NBIX

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

NBIX
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

PCVX

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

PCVX
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
Neurocrine Biosciences (NBIX) vs. Vaxcyte (PCVX): A comparison of their payout ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Metrics

Dividend metrics for Neurocrine Biosciences (NBIX) and Vaxcyte (PCVX)
MetricNBIXPCVX
Dividend Yield (TTM)0.00%0.00%
Dividend Payout Ratio (TTM)0.00%0.00%

Valuation

P/E Ratio (TTM)

An earnings multiple is available for just one side: Neurocrine Biosciences (NBIX) trades at 24.43 times trailing earnings, ranked against its peers, while Vaxcyte (PCVX) has no P/E ratio this period.

NBIX

Pharmaceuticals, Biotechnology & Life Sciences industry group

24.43

Max
85.34
Q3
43.46
Median
26.69
NBIX
24.43
Q1
13.30
Min
0.07

PCVX

Pharmaceuticals, Biotechnology & Life Sciences industry group

--

Max
85.34
Q3
43.46
Median
26.69
Q1
13.30
Min
0.07
PCVX
--
Loading chart…
Neurocrine Biosciences (NBIX) vs. Vaxcyte (PCVX): PCVX does not report P/E ratio, so it has no value marker; NBIX is benchmarked against the Pharmaceuticals, Biotechnology & Life Sciences industry group.

P/S Ratio (TTM)

A sales-based read is only available for Neurocrine Biosciences (NBIX), whose P/S ratio of 4.50 ranks against industry peers; Vaxcyte (PCVX) reports no figure this period.

NBIX

Pharmaceuticals, Biotechnology & Life Sciences industry group

4.50

Max
58.18
Q3
25.77
Median
7.30
NBIX
4.50
Q1
3.01
Min
0.01

PCVX

Pharmaceuticals, Biotechnology & Life Sciences industry group

--

Max
58.18
Q3
25.77
Median
7.30
Q1
3.01
Min
0.01
PCVX
--
Loading chart…
Neurocrine Biosciences (NBIX) vs. Vaxcyte (PCVX): PCVX does not report P/S ratio, so it has no value marker; NBIX is benchmarked against the Pharmaceuticals, Biotechnology & Life Sciences industry group.

P/B Ratio (MRQ)

On P/B ratio, both Neurocrine Biosciences (NBIX) at 4.30 and Vaxcyte (PCVX) at 3.83 are valued close to their industries’ norm against book — neither stands out from peers.

NBIX

Pharmaceuticals, Biotechnology & Life Sciences industry group

4.30

Max
13.53
Q3
6.54
NBIX
4.30
Median
3.25
Q1
1.69
Min
-5.59

PCVX

Pharmaceuticals, Biotechnology & Life Sciences industry group

3.83

Max
13.53
Q3
6.54
PCVX
3.83
Median
3.25
Q1
1.69
Min
-5.59
Loading chart…
Neurocrine Biosciences (NBIX) vs. Vaxcyte (PCVX): A comparison of their P/B ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Valuation Metrics

Valuation metrics for Neurocrine Biosciences (NBIX) and Vaxcyte (PCVX)
MetricNBIXPCVX
P/E Ratio (TTM)24.43--
P/S Ratio (TTM)4.50--
P/B Ratio (MRQ)4.303.83
Free Cash Flow Yield (TTM)6.11%-5.24%